Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis

Y. Wang, W. C. Huang, C. Y. Wang, C. C. Tsai, C. L. Chen, Yu-Tzu Chang, J. I. Kai, C. F. Lin

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background and purpose: Excessive inflammation and apoptosis are pathological features of endotoxaemic acute renal failure. Activation of glycogen synthase kinase-3 (GSK-3) is involved in inflammation and apoptosis. We investigated the effects of inhibiting GSK-3 on lipopolysaccharide (LPS)-induced acute renal failure, nuclear factor-kB (NF-kΒ), inflammation and apoptosis. Experimental approach: The effects of inhibiting GSK-3 with inhibitors, including lithium chloride (LiCl) and 6-bromoindirubin-3-oxime (BIO), on LPS-treated (15 mg-kg-1) C3H/HeN mice (LiCl, 40 mg-kg-1 and BIO, 2 mg-kg-1) and LPS-treated (1 mg-mL-1) renal epithelial cells (LiCl, 20 mM and BIO, 5 mM) were studied. Mouse survival was monitored and renal function was analysed by histological and serological examination. Cytokine and chemokine production, and cell apoptosis were measured by enzyme-linked immunosorbent assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling staining, respectively. Activation of NF-kB and GSK-3 was determined by immunostaining and Western blotting, respectively. Key results: Mice treated with GSK-3 inhibitors showed decreased mortality, renal tubular dilatation, vacuolization and sloughing, blood urea nitrogen, creatinine and renal cell apoptosis in response to endotoxaemia. Inhibiting GSK-3 reduced LPS-induced tumour necrosis factor-a (TNF-a) and CCL5/RANTES (released upon activation of normal T-cells) in vivo in mice and in vitro in murine kidney cortical collecting duct epithelial M1 cells. Inhibiting GSK-3 did not block TNF-a-induced cytotoxicity in rat kidney proximal tubular epithelial NRK52E or in M1 cells.Conclusions and implications: These results suggest that GSK-3 inhibition protects against endotoxaemic acute renal failure mainly by down-regulating pro-inflammatory TNF-a and RANTES.

Original languageEnglish
Pages (from-to)1004-1013
Number of pages10
JournalBritish Journal of Pharmacology
Volume157
Issue number6
DOIs
Publication statusPublished - 2009 Oct 29

Fingerprint

Glycogen Synthase Kinase 3
Acute Kidney Injury
Apoptosis
Inflammation
Kidney
Lithium Chloride
Lipopolysaccharides
Chemokine CCL5
Oximes
Tumor Necrosis Factor-alpha
Collecting Kidney Tubules
Epithelial Cells
Endotoxemia
DNA Nucleotidylexotransferase
Inbred C3H Mouse
NF-kappa B
Blood Urea Nitrogen
Biotin
Chemokines
Dilatation

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Wang, Y. ; Huang, W. C. ; Wang, C. Y. ; Tsai, C. C. ; Chen, C. L. ; Chang, Yu-Tzu ; Kai, J. I. ; Lin, C. F. / Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis. In: British Journal of Pharmacology. 2009 ; Vol. 157, No. 6. pp. 1004-1013.
@article{24cbee6c02504296b298daa91af86a17,
title = "Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis",
abstract = "Background and purpose: Excessive inflammation and apoptosis are pathological features of endotoxaemic acute renal failure. Activation of glycogen synthase kinase-3 (GSK-3) is involved in inflammation and apoptosis. We investigated the effects of inhibiting GSK-3 on lipopolysaccharide (LPS)-induced acute renal failure, nuclear factor-kB (NF-kΒ), inflammation and apoptosis. Experimental approach: The effects of inhibiting GSK-3 with inhibitors, including lithium chloride (LiCl) and 6-bromoindirubin-3-oxime (BIO), on LPS-treated (15 mg-kg-1) C3H/HeN mice (LiCl, 40 mg-kg-1 and BIO, 2 mg-kg-1) and LPS-treated (1 mg-mL-1) renal epithelial cells (LiCl, 20 mM and BIO, 5 mM) were studied. Mouse survival was monitored and renal function was analysed by histological and serological examination. Cytokine and chemokine production, and cell apoptosis were measured by enzyme-linked immunosorbent assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling staining, respectively. Activation of NF-kB and GSK-3 was determined by immunostaining and Western blotting, respectively. Key results: Mice treated with GSK-3 inhibitors showed decreased mortality, renal tubular dilatation, vacuolization and sloughing, blood urea nitrogen, creatinine and renal cell apoptosis in response to endotoxaemia. Inhibiting GSK-3 reduced LPS-induced tumour necrosis factor-a (TNF-a) and CCL5/RANTES (released upon activation of normal T-cells) in vivo in mice and in vitro in murine kidney cortical collecting duct epithelial M1 cells. Inhibiting GSK-3 did not block TNF-a-induced cytotoxicity in rat kidney proximal tubular epithelial NRK52E or in M1 cells.Conclusions and implications: These results suggest that GSK-3 inhibition protects against endotoxaemic acute renal failure mainly by down-regulating pro-inflammatory TNF-a and RANTES.",
author = "Y. Wang and Huang, {W. C.} and Wang, {C. Y.} and Tsai, {C. C.} and Chen, {C. L.} and Yu-Tzu Chang and Kai, {J. I.} and Lin, {C. F.}",
year = "2009",
month = "10",
day = "29",
doi = "10.1111/j.1476-5381.2009.00284.x",
language = "English",
volume = "157",
pages = "1004--1013",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "6",

}

Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis. / Wang, Y.; Huang, W. C.; Wang, C. Y.; Tsai, C. C.; Chen, C. L.; Chang, Yu-Tzu; Kai, J. I.; Lin, C. F.

In: British Journal of Pharmacology, Vol. 157, No. 6, 29.10.2009, p. 1004-1013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis

AU - Wang, Y.

AU - Huang, W. C.

AU - Wang, C. Y.

AU - Tsai, C. C.

AU - Chen, C. L.

AU - Chang, Yu-Tzu

AU - Kai, J. I.

AU - Lin, C. F.

PY - 2009/10/29

Y1 - 2009/10/29

N2 - Background and purpose: Excessive inflammation and apoptosis are pathological features of endotoxaemic acute renal failure. Activation of glycogen synthase kinase-3 (GSK-3) is involved in inflammation and apoptosis. We investigated the effects of inhibiting GSK-3 on lipopolysaccharide (LPS)-induced acute renal failure, nuclear factor-kB (NF-kΒ), inflammation and apoptosis. Experimental approach: The effects of inhibiting GSK-3 with inhibitors, including lithium chloride (LiCl) and 6-bromoindirubin-3-oxime (BIO), on LPS-treated (15 mg-kg-1) C3H/HeN mice (LiCl, 40 mg-kg-1 and BIO, 2 mg-kg-1) and LPS-treated (1 mg-mL-1) renal epithelial cells (LiCl, 20 mM and BIO, 5 mM) were studied. Mouse survival was monitored and renal function was analysed by histological and serological examination. Cytokine and chemokine production, and cell apoptosis were measured by enzyme-linked immunosorbent assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling staining, respectively. Activation of NF-kB and GSK-3 was determined by immunostaining and Western blotting, respectively. Key results: Mice treated with GSK-3 inhibitors showed decreased mortality, renal tubular dilatation, vacuolization and sloughing, blood urea nitrogen, creatinine and renal cell apoptosis in response to endotoxaemia. Inhibiting GSK-3 reduced LPS-induced tumour necrosis factor-a (TNF-a) and CCL5/RANTES (released upon activation of normal T-cells) in vivo in mice and in vitro in murine kidney cortical collecting duct epithelial M1 cells. Inhibiting GSK-3 did not block TNF-a-induced cytotoxicity in rat kidney proximal tubular epithelial NRK52E or in M1 cells.Conclusions and implications: These results suggest that GSK-3 inhibition protects against endotoxaemic acute renal failure mainly by down-regulating pro-inflammatory TNF-a and RANTES.

AB - Background and purpose: Excessive inflammation and apoptosis are pathological features of endotoxaemic acute renal failure. Activation of glycogen synthase kinase-3 (GSK-3) is involved in inflammation and apoptosis. We investigated the effects of inhibiting GSK-3 on lipopolysaccharide (LPS)-induced acute renal failure, nuclear factor-kB (NF-kΒ), inflammation and apoptosis. Experimental approach: The effects of inhibiting GSK-3 with inhibitors, including lithium chloride (LiCl) and 6-bromoindirubin-3-oxime (BIO), on LPS-treated (15 mg-kg-1) C3H/HeN mice (LiCl, 40 mg-kg-1 and BIO, 2 mg-kg-1) and LPS-treated (1 mg-mL-1) renal epithelial cells (LiCl, 20 mM and BIO, 5 mM) were studied. Mouse survival was monitored and renal function was analysed by histological and serological examination. Cytokine and chemokine production, and cell apoptosis were measured by enzyme-linked immunosorbent assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling staining, respectively. Activation of NF-kB and GSK-3 was determined by immunostaining and Western blotting, respectively. Key results: Mice treated with GSK-3 inhibitors showed decreased mortality, renal tubular dilatation, vacuolization and sloughing, blood urea nitrogen, creatinine and renal cell apoptosis in response to endotoxaemia. Inhibiting GSK-3 reduced LPS-induced tumour necrosis factor-a (TNF-a) and CCL5/RANTES (released upon activation of normal T-cells) in vivo in mice and in vitro in murine kidney cortical collecting duct epithelial M1 cells. Inhibiting GSK-3 did not block TNF-a-induced cytotoxicity in rat kidney proximal tubular epithelial NRK52E or in M1 cells.Conclusions and implications: These results suggest that GSK-3 inhibition protects against endotoxaemic acute renal failure mainly by down-regulating pro-inflammatory TNF-a and RANTES.

UR - http://www.scopus.com/inward/record.url?scp=70350337981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350337981&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2009.00284.x

DO - 10.1111/j.1476-5381.2009.00284.x

M3 - Article

VL - 157

SP - 1004

EP - 1013

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 6

ER -